Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O, Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M.
Cramer P, et al. Among authors: hallek m.
Blood. 2021 Nov 11;138(19):1805-1816. doi: 10.1182/blood.2020010484.
Blood. 2021.
PMID: 34086865
Free PMC article.
Clinical Trial.